Hr Her2 News Today

Hard questions on maui. How did this wildfire start . How did it grow so fast . Destroy lives all with so little warning . Now a top official in charge of the response to that crisis has quit even as he stands up for how his agency handled the disaster. Plus a historic hurricane. Hilary is now a huge category four storm. It could be the first storm of its kind to hit california in some 84 years. Some areas could get a years worth of rain in just one day. And justice deferred. Donald trumps legal...

Pooja Advani, MBBS, MD, discusses the potential utilization of capivasertib plus fulvestrant in hormone receptor–positive, HER2-negative breast cancers with PIK3/AKT/PTEN pathway alterations.

Investigators continue to evaluate HER2 expression as well as CDK4/6 inhibitor use for hormone receptor–positive/HER2-negative breast cancer.

In breast cancer coverage this year, topline results from the phase 3 NATALEE trial made waves in March, with our other most-read content in the space covering an expanded indication for abemaciclib, revised screening recommendations, a new potential treatment to reduce radiation exposure, and the benefits of diet and exercise on patient outcomes.

This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.

Dr Kettle provide insights into unmet needs surrounding treatment of metastatic breast cancer.

With their final thoughts, the panelists provide key takeaways from their conversation regarding CDK4/6 inhibitor therapy in treatment of HR+/HER2- metastatic breast cancer.

Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, presented by The American Journal of Managed Care® in partnership with Emory's Winship Cancer Institute.

Exclusive first look at a scathing report about a health care giant. the allegations and what the company says, in our nbc news investigatioion. hr+r+ her2- metaststatic breasast cancer hr+r+ her2- are liviving longer r with kisq. so, longng live famimily . are liviving longer r with kisq. long l live dreamsms. and long l live you. long l live dreamsms. kisqali isis a pill prproven to helelp women lilive longer when takaken with to helelp women lilive longer an aroromatase inhnhibito. to helelp ...